| Excerpt | Relevance | Reference |
|---|
| "Preventively using topical betaxolol can significantly decrease the incidence, VAS score, and grading of EGFR-TKI-induced paronychia." | 8.02 | Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study. ( Chen, CB; Chen, KH; Chen, MJ; Chung, WH; Fang, YF; Hsu, PC; Ko, HW; Ko, YS; Li, SH; Lin, YJ; Lu, CW; Shih, FY; Su Pang, JH; Tseng, LC; Wang, CL; Wang, TY; Wu, CE; Yen, CF, 2021) |
| "Data from a series of 35 non-small cell lung cancer cases suffering from EGFR inhibitor-induced paronychia with pyogenic granuloma-like lesions of digits treated with betaxolol 0." | 7.96 | Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study. ( Chi, CC; Chung, WH; Hsu, CK; Ko, YS; Lee, CN; Lu, CW; Pang, JS; Wang, CL; Wang, CW; Yang, HS; Yen, CF, 2020) |
| "Preventively using topical betaxolol can significantly decrease the incidence, VAS score, and grading of EGFR-TKI-induced paronychia." | 4.02 | Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study. ( Chen, CB; Chen, KH; Chen, MJ; Chung, WH; Fang, YF; Hsu, PC; Ko, HW; Ko, YS; Li, SH; Lin, YJ; Lu, CW; Shih, FY; Su Pang, JH; Tseng, LC; Wang, CL; Wang, TY; Wu, CE; Yen, CF, 2021) |
| "Data from a series of 35 non-small cell lung cancer cases suffering from EGFR inhibitor-induced paronychia with pyogenic granuloma-like lesions of digits treated with betaxolol 0." | 3.96 | Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study. ( Chi, CC; Chung, WH; Hsu, CK; Ko, YS; Lee, CN; Lu, CW; Pang, JS; Wang, CL; Wang, CW; Yang, HS; Yen, CF, 2020) |